| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-12-18 | Compugen (Israel) Johns Hopkins University (USA - MD) | B7/CD28-like immune checkpoint candidates | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-12-18 | Enamine (Ukraine) Sanofi (France) | drug-like screening compounds | collaboration |
Technology - Services | Collaboration agreement | |
| 2014-12-18 | The Medicines Company (USA - NJ) SciClone Pharmaceuticals (USA - CA, China) | Angiomax® (bivalirudin), Cleviprex® (clevidipine) | patients undergoing percutaneous coronary intervention (PCI), reduction of blood pressure | licensing commercialisation |
Cardiovascular diseases | Licensing agreement |
| 2014-12-18 | Novo Nordisk (Denmark) Xencor (USA -CA) | novel biologic drug candidates combining Xencor XmAb® bispecific and immune inhibitor technologies | collaboration licensing |
undisclosed | Licensing agreement | |
| 2014-12-16 | Galapagos (Belgium) Janssen Pharmaceutica, a J&J company (USA - NJ) | GLPG1205, GLPG2196 | inflammatory bowel disease | licensing |
Gastrointestinal diseases - Digestive diseases - Inflammatory diseases | Licensing agreement |
| 2014-12-16 | Integragen (France) investigators from the PICCOLO study | oncology biomarker hsa-miR-31-3p | metastatic colorectal cancer | Cancer - Oncology | Establishment of a new subsidiary in the EU | |
| 2014-12-16 | BioLineRx (Israel) Novartis (Switzerland) | up to three programs identified and presented by BioLineRx | development commercialisation |
Development agreement | ||
| 2014-12-16 | Gamamabs (France) Curie-Cancer (France) | 3C23K | gynecological cancers including ovarian cancer | R&D collaboration |
Cancer - Oncology | R&D agreement |
| 2014-12-15 | Novadip Biosciences (Belgium) | independent director | nomination | Regenerative medicine - Bone diseases | Nomination | |
| 2014-12-15 | OPKO Health (USA - FL) Pfizer (USA - NY) | long-acting human growth hormone (hGH-CTP) | growth hormone deficiency, growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age | development commercialisation |
Genetic diseases - Endocrine diseases - Hormonal diseases | Development agreement |
| 2014-12-15 | Gilead (USA - CA) | vice-president | nomination | Cancer - Oncology - Hepatic diseases - Infectious diseases | Nomination | |
| 2014-12-15 | Khondrion (The Netherlands) | chief medical officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-12-15 | Atox Bio (Israel) | chairman of the board of directors | nomination | Infectious diseases | Nomination | |
| 2014-12-15 | Silence Therapeutics (UK) | member of the board of directors | nomination | Cancer - Oncology - Metabolic diseases - Rare diseases | Nomination | |
| 2014-12-11 | Nestle Skin Health (Switzerland) Galderma (France) Global Coalition on Aging (GCOA) | Nestlé Skin Health Investigation, Education and Longevity Development (SHIELD) network | opening of new premises | Cancer - Oncology -Dermatological diseases - Skin health | Opening of new premises | |
| 2014-12-11 | Asceneuron (Switzerland) | member of the board of directors | nomination | Neurodegenerative diseases | Nomination | |
| 2014-12-10 | Abcodia (UK) Cancer Research UK (UK) Cancer Research Technology (CRT) (UK) Caprion (Canada) Asuragen (USA - TX) AIT Austrian Institute of Technology (Austria) | new blood tests | R&D |
Cancer - Oncology - Diagnostic | Collaboration agreement | |
| 2014-12-10 | Noxxon (Germany) | member of the supervisory board | nomination | Nomination | ||
| 2014-12-10 | UCB (Belgium) Daiichi Sankyo (Japan) | Vimpat® (lacosamide) | epilepsy | production manufacturing distribution commercialisation |
CNS diseases - Neurological diseases | Commercialisation agreement |
| 2014-12-09 | Pharnext (France) | member of the board of directors | nomination | Nomination |
